Immunologix Laboratories announces the addition of Linda Terry, PhD as Executive Director, Biomarker Sciences

Tampa, FL – Immunologix Laboratories announces the addition of Linda Terry, PhD as Executive Director, Biomarker Sciences. Immunologix continues to make robust investment in senior level leadership across the organization to provide strong foundational support for sustained laboratory growth.

“We are excited to build upon the growth we experienced in 2020 and the addition of Dr. Terry to our Biomarker Sciences organization demonstrates our commitment to attracting the right senior leadership to support our strong growth trajectory in 2021 and beyond. Dr. Terry brings depth and breadth of expertise in biomarker strategy, assay development, validation and clinical implementation, coupled with operational acumen that ensures reliable delivery of high-quality biomarker data,” notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. CSO and Head of Translational Sciences, Dr. Lauren Stevenson, adds “Dr. Terry’s proven track record as a thought leader in Biomarker Sciences coupled with her extensive laboratory leadership experience and commitment to delivering scientifically driven strategic and technical solutions is perfectly aligned with our science-first mission.  Her extensive first-hand experience gained in academic and biotech/pharma settings enables Dr. Terry to fully appreciate our clients’ needs at different stages of drug development and translate them into tailored solutions.  In addition, Dr. Terry will serve as adjunct to the Translational Sciences team, strengthening the synergies between the laboratory and translational sciences and ensuring that our clients’ projects benefit from the rich diversity and depth of scientific expertise we’ve assembled here at Immunologix.”

A highly recognized scientific leader, Dr. Terry joins Immunologix from her most recent role as Group Lead, Exploratory Biomarkers, at GSK where she led a team of scientists developing and validating biomarker assays in support of early-stage programs from candidate selection to first in human trials. Dr. Terry graduated from University College London in the UK with a doctorate in immunology and her diverse career has traversed academia, government research and the pharmaceutical industry, enabling her to build strong foundational knowledge across multiple disease areas. She brings over two decades of experience in the development and implementation of biomarker strategies and associated assays with particular interest in building translational strategies that effectively drive early phases of drug development, from lead optimization through to proof of concept. Dr. Terry’s scientific network spans two continents, where she is a highly sought-after speaker and panelist at international conferences and has served as a core committee member of the Biomarker Focus Workshops for the European Bioanalytical Forum in 2019 and 2020.  An analytical problem solver with a passion for building highly collaborative teams focused on finding effective and efficient solutions that facilitate patient-focused drug development, Dr. Terry is also an impassioned people developer and coach, who firmly believes that an empowered and engaged employee community drives excellence and innovation. As such, she is a perfect fit with Immunologix Laboratories’ philosophy that great science is achieved by developing great scientists.

Dr. Terry commented, “I am thrilled to join Immunologix and have the privilege to work with an exceptional team of biomarker scientists who lead the field in this fast changing and expanding discipline.  Moving from Big Pharma to the CRO space means that I can positively impact a much broader and diverse portfolio of therapeutics, support some of the most innovative science across the industry and improve the lives of many more patients. As a life-long learner, I am also excited by the constant scientific and technical challenges presented by our projects and the opportunity to work through them as part of a team of critical, incisive thought partners.”

About Immunologix Laboratories
Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding based bioanalysis and expert scientific consultation from our Translational Sciences team. Our laboratory specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding based), PK, and Biomarker assays in support of preclinical and clinical studies. Translational Sciences provides dedicated scientific resources to advise, develop and implement scientific strategies and practical solutions for innovator development programs. Our fully customizable approach includes delivering stage appropriate biomarker & bioanalytical strategies, assay development and validation, study data interpretation and support for regulatory interactions and filings. Our exceptional scientific experts ensure that our client’s projects receive full benefit of the breadth and depth of experience gained over many decades within both contract laboratory and drug development organizations. Having bothTranslational Sciences and Laboratory expertise is unique within our industry, and this confluence of expertise enables our teams to deliver valuable scientific insights that can accelerate decision making and the course of drug development.

www.immunologixlabs.com

PRESS CONTACT INFORMATION
Michael J. Anderson
President and CEO, Immunologix Laboratories
1.813.324.1483
manderson@immunologixlabs.com

Immunologix Laboratories Expands Translational Sciences Team

Immunologix Laboratories announces two additions to the Translational Sciences division with Corinna Fiorotti, Ph.D. as Executive Director, Translational Sciences and Safa Alvandkouhi as Director, Business Operations. The continued growth of Translational Sciences highlights Immunologix Laboratories’ commitment to building an unparalleled model of scientific partnership with our clients.

“We are excited about expanding our Translational Sciences team with the addition of Dr. Fiorotti as an Executive Director. Dr. Fiorotti brings extensive bioanalytical experience in both traditional and emergent therapeutic modalities, including monoclonal antibodies, bispecific and multi-domain therapeutics, antibody-drug conjugates and cell and gene therapies. Our clients are already benefiting from her diversity of experience that spans both the biotech/pharma and CRO industries,” notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. CSO and Head of Translational Sciences, Dr. Lauren Stevenson, adds, “Dr. Fiorotti is a perfect fit for our science-first organization, bringing extensive first-hand drug development expertise coupled with a team-oriented, collaborative approach and a deep commitment to delivering the best scientific solutions to meet the needs of our clients’ projects.”

A highly recognized scientific leader, Dr. Fiorotti brings almost two decades of drug development experience which spans from research through clinical development, with expertise in building and executing on strategies for bioanalytical development. Dr. Fiorotti holds a Ph.D. in Immunology and Microbiology and completed a post-doctoral fellowship in Molecular Biology at Harvard Medical School, where her work was featured as a cover story in the journal Nature. In addition to her extensive expertise in development and validation of PK, ADA and cell-based assays, Dr. Fiorotti has established an exceptional track record of helping project teams identify the critical questions/decision points and developing strategies to address them. With the addition of Dr. Fiorotti, the Translational Sciences team continues to add exceptional depth and diversity of expertise that delivers proven strategy and results.

Dr. Fiorotti commented, “This is without question the most exciting and impactful role I have taken in my career.  I am taking advantage of this opportunity to combine my experience with the already industry-leading Translational Sciences team and senior management at Immunologix to integrate with our veteran staff, building successful and lasting partnerships with our clients.”

Immunologix Laboratories concurrently welcomes Safa Alvandkouhi, as Director of Business Operations, Translational Sciences.   Ms. Alvandkouhi holds a B.S. degree in Biochemistry from North Carolina State University and brings several years of combined experience gained at the laboratory bench as well as within business development. Leveraging this unique intersection of scientific and business talents, Ms. Alvandkouhi has focused her career on building long-term, sustainable partnerships with global biotech/pharma companies to optimally support their drug development endeavors.  At Immunologix, she will build on that experience to lead project management, business operations and scientific content development efforts for the Translational Sciences team. John Ryan, Executive Director of Business Development notes, “The Business Operations team is integral in ensuring proper intake and execution of our client’s programs. Ms. Alvandkouhi has already launched several operational excellence initiatives and is actively working with CSO Dr. Stevenson’s team to further develop the scope of the Translational Sciences Team’s scientific and consulting service offerings that will deliver state of the art solutions for our clients.”

Dr. Lauren Stevenson

Immunologix Laboratories Appoints Lauren Stevenson, Ph.D. As Chief Scientific Officer And Further Expands Translational Sciences Drug Development Expertise

TAMPA, Fla., — Immunologix Laboratories announces the appointment of Lauren Stevenson, Ph.D. as Chief Scientific Officer and further expands the Translational Sciences team, as Christopher Stebbins, Ph.D. joins the drug development experts as Scientific Director. Ensuring strong leadership and continuous scientific growth is a key objective for the organization.

“With Dr. Stevenson as Chief Scientific Officer, we are excited about the enhanced scientific and strength-focused team leadership she is bringing to our organization, as well as accelerating our industry-impacting initiatives,” notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. “We are already seeing immediate and demonstrated benefits for both our clients and internal scientists as she builds upon her deep strategic, scientific and results-oriented experience. Dr. Stevenson’s appointment further strengthens our industry leading scientific leadership team.”

A globally recognized thought leader, Dr. Stevenson is leveraging her 25+ years of drug development experience, which spans numerous disease indications and drug modalities. In this role, she will ensure science-first collaborations with clients to deliver proven strategy and results, while also maximizing synergies between Immunologix’s assay experts and the Translational Sciences Directors. Dr. Stevenson joined Immunologix Laboratories in April 2019, following her post as Senior Director & Head, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA). Together, with Dr. Devangi Mehta, she co-founded Translational Sciences in May 2019 and will continue to lead that function as part of her new role.

Dr. Stevenson commented, “I’m truly honored and humbled to take on this expanded role for Immunologix Laboratories and am fully committed to building a partnership model for our clients that is unique in the industry. In parallel, I’m equally excited and enthusiastic about growing our internal scientific community and building upon our culture of high science, collaboration and interdependence that maximizes opportunities to continuously learn from one another.”

Concurrently, Immunologix Laboratories welcomes Dr. Christopher Stebbins to the Translational Sciences team. Bringing two decades of drug development experience in large pharma/biotech, with expertise in building and executing on strategies for both biomarker and bioanalytical development, Dr. Stebbins joins from his previous post as Director, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA).

The Translational Sciences team of Immunologix Laboratories provides a dedicated partner and resource to advise, develop, and implement integrated strategies and solutions for innovator development programs from discovery to post-market. The expert team delivers stage appropriate biomarker, bioanalytical and clinical research strategies, scientific oversight of assay lifecycle management, study data analysis and interpretation, as well as support for regulatory interactions and document writing.

“The pace of growth across Translational Sciences has exceeded our expectations,” Dr. Stevenson comments. “This speaks to the demand for experts who can deliver across all stages of drug development and traverse the bioanalytical, biomarker and regulatory arenas with equal facility. With the addition of Dr. Stebbins, our Translational Sciences team, which also includes VP of Biomarker Sciences, John Allinson, now brings more than 100 years of collective experience to bear on our clients’ projects. Combined with our exceptional technical and laboratory expertise, we are redefining the CRO partnership landscape for our clients around the world.”

Dr. Stevenson will be presenting on “Preventing Misguided Guidance – Putting Biomarker Assay Validation in Context” on April 23, 2020 as part of Immunologix Laboratories’ webinar series. Registration for the event can be found here. To learn more about Immunologix Laboratories full capabilities and explore learning opportunities offered by the expert scientific team, visit www.immunologixlabs.com

About Immunologix Laboratories
Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding based bioanalysis coupled with expert scientific consultation from our Translational Sciences team. Our laboratory specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding based), PK, and Biomarker assays in support of preclinical and clinical studies. Translational Sciences provides dedicated scientific resources to advise, develop and implement scientific strategies and practical solutions for innovator development programs. Our fully customizable approach includes delivering stage appropriate biomarker & bioanalytical strategies, assay development and validation, study data interpretation and support for regulatory interactions and filings. Our exceptional scientific experts work together as an integrated team ensuring that our client’s projects receive full benefit of the breadth and depth of experience gained over many decades within both contract laboratory and drug development organizations. The integration of Translational Sciences with the laboratory is unique within our industry and this confluence of expertise enables our team to deliver valuable scientific insights that can accelerate decision making and the course of drug development.

PRESS CONTACT INFORMATION
Michael J. Anderson
President and CEO, Immunologix Laboratories
1.813.324.1483
manderson@immunologixlabs.com

Immunologix Laboratories Adds Accomplished Biotech Drug Development Experts To Launch Translational Sciences Division

Tampa, FL

With the launching of their Translational Sciences division, Immunologix Laboratories continues to strengthen it’s scientific and technical expertise to build an industry-leading drug development partner for clients and their bioanalytical and biomarker programs.

The new Translational Sciences team is led by Dr. Lauren Stevenson, following her post as Senior Director & Head, Development Biomarkers & Bioanalytical Sciences at Biogen (Cambridge, MA). She is joined by Dr. Devangi Mehta, who most recently served as Director, Development Biomarkers and Bioanalytical Sciences at Biogen. Both globally recognized thought leaders, Drs. Stevenson and Mehta will leverage their 40+ years of collective drug development experience, which spans numerous disease indications and drug modalities, to create enhanced synergy with Immunologix’s assay experts and deliver proven strategy and results for clients.

The Translational Sciences division will provide a dedicated partner and resource to advise, develop, and implement integrated strategies and solutions for innovator development programs from discovery to post-market, delivering stage appropriate biomarker, bioanalytical and clinical research strategies, scientific oversight of assay lifecycle management, study data analysis and interpretation, and supporting regulatory interactions and document writing. Drs. Stevenson and Mehta come with significant performance records that include both internal program successes through product launch, as well as data-driven influencing of regulatory guidance and industry best practices.

Dr. Stevenson commented: “I am truly excited and privileged to lead the Translational Sciences division and am looking forward to building a world class team of drug developers with deep biomarker and bioanalytical experience. Together we will pioneer a new model of scientific support that will actively leverage the diverse perspectives and expertise of the team to deliver highly vetted, pressure-tested strategies and scientific solutions to our clients.”

Immunologix President and CEO Dr. Michael Anderson adds: “We are very excited to announce the launch of our Tanslational Sciences division. The addition of Lauren and Devangi gives us an unparalleled, industry-leading assay strategy and implementation team. By combining their experience with that of John Allinson, our Vice President of Biomarker Services, and other members of our very experienced senior staff, we can offer our clients a level of scientific service that is unmatched in the bioanalytical lab industry.“

About Immunologix Laboratories
Immunologix Laboratories is a science-based GLP and GCP compliant immunoassay laboratory focused on ligand binding based bioanalysis and biomarkers. The lab specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding-based), PK, and Biomarker assays in support of preclinical and clinical trials. The Translational Sciences division provides enhanced experienced resources for technical strategy and implementation of bioanalytical and biomarker assays. Immunologix’s customer-focused service model allows it to customize project execution for each client in a timely manner. The entire team has many years of CRO and industry experience in development, validation, and application of immunoassay-based methods.

 

PRESS CONTACT INFORMATION
Michael J. Anderson
President and CEO, Immunologix Laboratories
1.813.324.1483
manderson@immunologixlabs.com

Biologics Development Services Becomes Immunologix Laboratories

Biologics Development Services becomes Immunologix Laboratories.
Immunologix Laboratories

Immunogenicity For Biotherapeutics

Advance Risk Assessment Strategies and Optimize the Prediction of Immune Response to Accelerate the Process from Concept to Approval

WCBNoTag

Improve your drug safety analysis with improved,
specific, and accurate immunogenicity information
so you can minimize the time it takes to gain
regulatory approval and increase speed to market


  • Hear firsthand perspectives from the FDA to gain insights and ask your questions to accelerate the approval process
  • Collaborate with peers and industry experts to develop solutions for predicting, anticipating, and mitigating risks created by potential immune responses
  • Discover cutting-edge technologies to improve immunogenicity testing
  • Improve the accuracy of your risk assessment by understanding how protein aggregation impacts immunogenic responses

Download Your
Copy Today!



B15193minibrochure


“An excellent program – extremely useful from a technical
perspective. The lessons from the case studies and discussions
will assist our group’s development efforts.”
– Thomas Klem, Scientist, Shire

 


Use Priority Code IMMUNO15BDS to Save 20%


Group Savings Available for Companies Registering 4+ Attendees

Register Now

Welcome to BDS: Biologics Development Services

Biologics Development Services (BDS) announced today the opening of their immunoassay laboratory in the Westshore area of Tampa, Florida. BDS provides large molecule bioanalytical services of the highest caliber to pharmaceutical and biotechnology companies across the United States. Because there is an art as well as science to immunoassay, BDS offers you the distinct advantage of management by one of the industry’s most noted experts. Equally advantageous is the fact that BDS has the expertise to develop unique reagents and de novo assays to further your company’s drug development program.